Ligand Pharmaceuticals Inc - Class B

NASDAQ: LGND
$69.89
+$1.36 (+2.0%)
Closing price April 23, 2024
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and licensing a diverse portfolio of therapeutic products. It has a range of treatments for multiple myeloma, acute lymphoblastic leukemia, rare kidney diseases, osteoporosis, and pneumococcal diseases among others. Its products include Kyprolis, Evomela, Rylaze, and Veklury for COVID-19 treatment. The company collaborates with industry giants like Amgen, Merck, and Pfizer, providing innovative solutions such as Captisol technology for drug formulation. Founded in 1987, Ligand is headquartered in Jupiter, Florida, contributing to healthcare advancements globally.

CEOs Buying Their Own Companies At A Discount (NLY, CHTR, D, EQY, GBX, HUN, LEAP, LGND, MBRG, MS, TIE, WIN)

Investors couldn’t have missed seeing the recent waves of new corporate share buyback plans. What they may have not noticed as clearly is the increasing trend in “legal insider trading” —...
Jon C. Ogg
Published:

Top Pre-Market Analyst Upgrades (AXYS, CRXL, DFT, LVLT, LGND, NOC, OXGN, PFE)
These are some of this morning’s top pre-market analyst upgrades and positive research calls from Wall Street this Thursday morning with over two hours until the market opens: Axsys...
Douglas A. McIntyre
Published:
Last Updated:

Biotech Bonanza: Ligand Takes out Pharmacopeia (LGND, PCOP)
This might not be the biggest of biotech mergers out there, but deals are continuing in the bio-space.  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has entered into a definitive merger...
Douglas A. McIntyre
Published:

The Week's Top Biotech Movers For Next Week (TRCA, ACOR, ISPH, ONCY, PCYC, SQNM, IDEV, LGND, AUXL)
Out of the daily movers this last week, many of the top winners and losers were from news in many of the smaller biotech stocks.  We prepared a list of the winners and sinners from our daily...
Douglas A. McIntyre
Published: